close

Agreements

Date: 2017-12-19

Type of information: Distribution agreement

Compound: LISA TRACKER® monitoring assays, auto-immunity IVD tests

Company: Theradiag (France) HOB Biotech Group (China)

Therapeutic area: Diagnostic - Autoimmune diseases - Immunological diseases

Type agreement: co-development - distribution

Action mechanism: theranostic test

Disease:

Details:

  • • On December 19, 2017, Theradiag provided an update on contracts renegotiation discussions with HOB Biotech. Contracts renegotiation discussions have been initiated by its Chinese partner HOB Biotech. These have now reached an impasse and it is not possible at this stage to anticipate the consequences of this situation on the HOB Biotech partnership or the launch of BioCLIA. The outcome of these discussions and the consequences of any decision will be detailed as soon as possible.
  • • On November 18, 2015, Theradiag and HOB Diagnostics announced they have initiated the commercialization in Asia of LISA TRACKER®, Theradiag's flagship biotherapy monitoring kits, by entering into a mutual distribution and development agreement with the HOB® Biotech Group. With this partnership, Theradiag is also gaining access to the highly-innovative and affordable allergy and auto-immunity IVD tests developed by HOB, which it will distribute in Europe. HOB is China's market leader in allergy and autoimmune in vitro diagnostic. With 20 years of experience in the distribution and development of high-quality immunoassays, HOB has developed a strong network of laboratory and hospital clients throughout Asia.
  • Under the terms of the cross-distribution agreement, HOB will proceed with the registration of LISA TRACKER® with Chinese authorities and become its exclusive distributor in China and Asia. It is estimated today that around 70 million people suffer from auto-immune diseases in China. The Chinese market for anti-TNFs biotherapies is expected to grow exponentially in the coming years as new biotherapies and biosimilars reach the market.
  • The companies have also agreed to initiate common R&D projects to develop new allergy, autoimmunity and monitoring solutions on a new innovative technology platform, sharing experience and expertise in their respective fields. These research projects will be initiated immediately, with potential to reach the market as early as 2017.
  • Theradiag will become HOB's exclusive distributor in the major European countries for its innovative allergy and auto-immunity immunoassays. Today, allergy and auto-immunity currently make up 45% of Theradiag's sales. Given the high quality and competitive prices of HOB's allergy and autoimmunity products, Theradiag estimates that the market for these new ranges in Europe could reach the same level of sales as the expected future sales of theranostics and so generating in the next years a substantial growth of its current IVD sales.

Financial terms:

Latest news:

Is general: Yes